Validation Data Gallery
|Positive WB detected in||rat liver tissue, A549 cells, SGC-7901 cells|
|Positive IP detected in||mouse liver tissue|
|Positive IHC detected in||human liver tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||HepG2 cells|
|Western Blot (WB)||WB : 1:500-1:2000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:500-1:1000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:20-1:200|
|Immunofluorescence (IF)||IF : 1:10-1:100|
|Sample-dependent, check data in validation data gallery|
The immunogen of 24766-1-AP is INSIG2 Fusion Protein expressed in E. coli.
|Tested Reactivity||human, mouse, rat|
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||INSIG2 fusion protein Ag14072|
|Full Name||INSIG 2|
|Calculated molecular weight||225 aa, 25 kDa|
|Observed molecular weight||30 kDa|
|GenBank accession number||BC022475|
|Gene ID (NCBI)||51141|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
INSIG2 mediates feedback control of cholesterol synthesis by controlling SCAP and HMGCR. INSIG2 may bring HMGCR into ubiquitin-mediated proteasomal degradation. Insig2 protein are endoplasmic reticulum proteins that block the processing of sterol regulatory element binding proteins (SREBPs) by binding to SREBP cleavage-activating protein (SCAP), and thus prevent SCAP from escorting SREBPs to the Golgi. INSIG-2 may play an important role in therapy of hypercholesterolemia.
|Product Specific Protocols|
|WB protocol for INSIG2 antibody 24766-1-AP||Download protocol|
|IHC protocol for INSIG2 antibody 24766-1-AP||Download protocol|
|IF protocol for INSIG2 antibody 24766-1-AP||Download protocol|
|IP protocol for INSIG2 antibody 24766-1-AP||Download protocol|
|Click here to view our Standard Protocols|
Am J Cancer Res
p38α/S1P/SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma.
Int J Biol Sci
The GR-gp78 Pathway is involved in Hepatic Lipid Accumulation Induced by Overexpression of 11β-HSD1.
CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing.
The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis.